Neoadjuvant and Perioperative Immunotherapy for Resectable Esophageal Squamous Cell Carcinoma: Current Evidence, Endpoints, and Clinical Integration.
Immunotherapy shows sufficient promise in early trials to warrant continued testing as standard treatment for resectable esophageal cancer.
This PubMed record reports a narrative review about Neoadjuvant and Perioperative Immunotherapy for Resectable Esophageal Squamous Cell Carcinoma: Current Evidence, Endpoints, and Clinical Integration. The available abstract indicates Overall, current data support continued phase III evaluation of ICI-containing strategies with mature event-free and overall survival endpoints and with comparators appropriate to regional treatment standards.
What the study was
- Study design
- Narrative review
- Population
- Human participants
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Journal of gastrointestinal cancer
Why it surfaced
Narrative review; directly matches Early cancer detection. Conservative abstract-level score 7/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.